Representing Animals Foundation
15.5.2024 21:04:31 CEST | ACCESS Newswire | Press release
SOUTHAMPTON, ENGLAND / ACCESSWIRE / May 15, 2024 / A new study has increased confidence in the apparent benefits of vegan diets for dogs. The study reanalysed data within a key 2022 study of 2,536 dogs - the largest published study within this field. That study concluded that the healthiest and least hazardous dog foods were nutritionally-sound vegan diets. However, owner opinions of health were included, which may not always be reliable. For example, owners committed to feeding vegan or meat-based diets might sometimes fail to recognise or report subsequent health problems.
The new study used additional statistical methods, including machine learning, to analyse owner opinions of health. It found these were minimally affected when vegan diets were fed. Stated Prof. Andrew Knight - lead author of the original study, "I was relieved to see confirmation that feeding vegan diets had minimal impact on owner opinions about health. This increases my confidence in the reliability of the owner opinions we used."
The new study focused specifically on subjective owner opinions of health, in contrast to the original study which examined seven general indicators of illness, including more objective data such as the frequency of medication use, therapeutic diet use, and veterinary visits. The original study also analysed the reported assessments of veterinarians concerning dog health, as well the prevalence of 22 of the most common health disorders in dogs. Stated Knight, "The large number of health parameters we studied, and the very large number of dogs included, provide a high degree of confidence in the results."
By May 2024 there were 10 studies in dogs, and three in cats, demonstrating equivalent or superior health outcomes when vegan diets are fed, as well as one systematic review covering both species. In April 2024, the longest, most comprehensive peer-reviewed study demonstrated that dogs fed nutritionally-sound vegan diets maintained health outcomes as well as those fed meat. The study comprehensively analysed blood cells and biochemistry, blood nutrient levels, urine, veterinary clinical parameters, and monthly pet owner questionnaires. It studied 15 dogs fed solely vegan diets for an entire year - just under one tenth of an average dog lifespan, or around seven human years. Another 2022 study demonstrated that 1,052 dogs fed vegan diets lived 1.5 years longer, on average, than dogs fed meat. Stated Prof. Knight, "This equates to around an extra decade of life for a human. Additionally, dogs fed vegan diets appear less impacted by certain health problems that impair quality of life. However, it is essential that any diets fed be nutritionally-sound."
Prof. Knight also analysed the environmental benefits of vegan pet diets in a major recent study. This demonstrated that if all the world's pet dogs went vegan, more greenhouse gases than those emitted by the UK would be saved. Knight stated that "Climate change is becoming a major threat to life on Earth. With the livestock sector a leading cause, substantial dietary change is now essential, and that includes pet diets."
Contact Information
Andrew Knight
Veterinary Professor of Animal Welfare
andrew.knight@winchester.ac.uk
SOURCE: Prof. Andrew Knight
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
